Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Anti-PD-1/PD-L1 therapies are crucial for anti-tumor activity, correlating with T cell infiltration.
• TGF-β contributes to T cell exclusion, and its inhibition can improve anti-PD-L1 efficacy, but clinical use is limited by toxicity.
• Understanding transcriptional changes in the tumor microenvironment is key to overcoming resistance to PD-L1 blockade.

Purpose of the Study:

• To elucidate the transcriptomic effects of PD-L1 and TGF-β blockade in the tumor microenvironment.
• To identify novel strategies to enhance T cell infiltration and the efficacy of anti-PD-L1 therapy.
• To find alternatives or complementary approaches to current combination therapies.

Main Methods:

• Single-cell RNA sequencing was employed in a mouse model to analyze transcriptomic changes.
• Nearly 30,000 single cells within the tumor and microenvironment were studied.
• Publicly available human cancer transcriptome data was analyzed for chemokine gene associations.

Main Results:

• Combination blockade upregulated immune response and chemokine genes (e.g., CCL5) in macrophages.
• Extracellular matrix genes were downregulated in fibroblasts.
• The chemokine CCL5 was linked to immune cell infiltration in human cancers and enhanced anti-PD-L1 efficacy in vivo.

Conclusions:

• Data can inform translational strategies, potentially serving as biomarkers or identifying new therapeutic targets.
• CCL5 administration enhanced cytotoxic lymphocytes and anti-tumor activity, suggesting its potential therapeutic role.
• Findings offer alternatives to anti-PD-L1 plus anti-TGF-β combination therapy to overcome resistance.